No signs of GVHD in the anti-CD3–conditioned chimeric recipients. (A) Representatives of GVHD-free recipients conditioned with anti-CD3 and GVHD recipients conditioned with TBI. (B) Body weight change of recipients over a follow-up period of 28 weeks after BMT. ⬡ indicates anti-CD3–conditioned chimeric NOD recipients; , NOD mice given anti-CD3–conditioning only; and ▾, TBI-conditioned chimeric NOD recipients. Values are mean ± SE of anti-CD3–conditioned chimeric recipients (n = 12), NOD mice given anti-CD3–conditioning only (n = 12), and TBI-conditioned chimeric recipients (n = 8). (C) Histology of skin and small intestine tissues of the anti-CD3–conditioned chimeric recipients (top row), NOD mice given anti-CD3–conditioning only (middle row), and TBI-conditioned chimeric recipients 50 days after BMT (bottom row). One representative of 4 recipients examined in each group is shown.